PAPA JOSEPH C 4

What Happened Joseph C. Papa, President, CEO and a director of Emergent BioSolutions Inc. (EBS), was granted 187,708 restricted stock units (RSUs) on April 29, 2026. The Form 4 reports the award as an acquisition (code A) at a grant price of $0.00 (i.e., an RSU award, not an open‑market purchase or sale). The RSUs represent the right to receive one share of common stock per unit when they vest.

Key Details

• Transaction date and type: 2026-04-29 — Grant/Award (Form 4 code A).
• Shares/units granted: 187,708 RSUs; reported grant price $0.00.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote highlights: the grant was approved by the Compensation Committee on March 2, 2026, conditioned on stockholder approval of an amendment to the 2006 Stock Incentive Plan; stockholders approved the amended plan on April 29, 2026. The RSUs vest in three annual installments beginning on the anniversary of the approval date, assuming continued service, and each RSU equals the right to one share (subject to adjustments).
• Filing timeliness: Form 4 filed 2026-05-01 for a 2026-04-29 transaction — appears timely under the Form 4 two‑business‑day rule.

Context Restricted stock units are compensation awards that convert to shares only as they vest; they are not an immediate cash purchase or sale. The economic value and any tax consequences to the insider depend on Emergent’s future share price at vesting and the terms of the grant agreement. This filing documents an executive compensation award rather than a market trade.